Semax Providers in Pennsylvania

About Semax

Semax is a synthetic heptapeptide derived from ACTH(4-10), developed in Russia and approved there for stroke and cognitive indications. It is not approved by the FDA for any use in the United States. Its mechanism work — increasing BDNF and TrkB expression in the brain — is well documented in preclinical studies, while its clinical trial literature is largely Russian-language and has not been independently replicated in English-language journals. In July 2026 an FDA advisory committee recommended Semax for the 503A bulks list; a recommendation is advisory and did not change its legal status.